finmarketnews.com
news-details
Health,Watchlist,healthcare stocks

3 HealthTech Stocks Trending Now PTCT stock, KRYS stock, MRTX stock

Powered by healthtechmovers.com

According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist.  That staff here at finmarketnews.com, will continue to monitor these healthtech companies to see if the momentum continues. FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..

PTC Therapeutics, PTCT
Recent PTCT Stock Price: $43.46
Summary:
PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

Colin Bristow analyst at UBS reiterates coverage on PTC Therapeutics (PTCT) stock in the energy sector with a Hold rating and has set PTCT's stock price target at $ 52.

TipRanks.com reports that PTC Therapeutics currently has 13 analysts offering 12-month price targets on PTCT and the consensus is a Hold rating with an average stock price target of $51.62.  The most recent PTCT stock price we have is $43.46 and we are not making any PTCT forecasts at this time.

In addition, TradingView issued a Strong Sell rating for PTCT over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on PTCT. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on PTCT, please click here >>

Krystal Biotech, KRYS
Recent KRYS Stock Price: $117.39
Summary:
Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

Alec Stranahan analyst at Bank of America Securities reiterates coverage on Krystal Biotech (KRYS) stock in the energy sector with a Buy rating and has set KRYS's stock price target at $ 140.

TipRanks.com reports that Krystal Biotech currently has 8 analysts offering 12-month price targets on KRYS and the consensus is a Strong Buy rating with an average stock price target of $141.00.  The most recent KRYS stock price we have is $117.39 and we are not making any KRYS forecasts at this time.

In addition, TradingView issued a Buy rating for KRYS over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KRYS. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on KRYS, please click here >>

Mirati Therapeutics, MRTX
Recent MRTX Stock Price: $38.40
Summary:
Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.

Jay Olson analyst at Oppenheimer reiterates coverage on Mirati Therapeutics (MRTX) stock in the energy sector with a Buy rating and has set MRTX's stock price target at $ 56.

TipRanks.com reports that Mirati Therapeutics currently has 12 analysts offering 12-month price targets on MRTX and the consensus is a Moderate Buy rating with an average stock price target of $61.33.  The most recent MRTX stock price we have is $38.40 and we are not making any MRTX forecasts at this time.

In addition, TradingView issued a Strong Sell rating for MRTX over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MRTX. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on MRTX, please click here >>



The editors at finmarketnews.com use a variety of research tools to generate our watchlists and research reports.  One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.

Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================